GlassScriptPhysician profile
Jeffrey Ashby
NPI 1053312702
$14,691.63
in general payments reported to CMS, 2019-2025
47 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $1,488 · 2021: $1,911 · 2022: $2,388 · 2023: $2,421 · 2024: $2,482 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,973.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,113.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,817.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,397.94 | 2019-2025 | |
| Lilly USA, LLC | $1,334.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,146.41 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,022.29 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $971.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $683.15 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $548.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $412.01 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $396.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $338.27 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Biohaven Pharmaceutical Holding Company LTD. | $312.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $283.25 | 2019-2025 | Eliquis, Camzyos |
| Allergan, INC. | $177.27 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ashby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.